Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma (NHL) patient's risk of dying. That is the finding of a new study published in the December 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.

Combined positron emission tomography (PET) and computed tomography (CT) imaging of lymphoma patients is a more effective method to evaluate response to radiation therapy, and may help patients avoid unnecessary follow-up treatments, a study by researchers at the University of Southern California (USC) suggests.

The immune system's powerful cellular mutation and repair processes appear to offer important clues as to how lymphatic cancer develops, Yale School of Medicine researchers report this week in Nature.

A new review article from the journal Dermatologic Therapy reveals that rituximab, a drug used to treat lymphoma, is now becoming used by dermatologists to treat various dangerous skin diseases.

Primary and metastatic tumors of the spleen are described as unusual, excluding involvement by lymphoma. Indeed, isolated splenic metastasis from colorectal carcinoma is not a common occurrence. Its rareness has been hypothetically explained by several characteristics of the spleen, such as anatomical, histological and immunological features.

University of Pennsylvania researchers and their colleagues at the Wistar Institute and University of Oxford have discovered the molecular process by which the PAX5 protein, necessary for lymphocyte development, promotes the growth of common lymphomas, thereby unveiling a potential new target in the fight against cancer.

New data produced by Andrei Thomas-Tikhonenko and colleagues at the University of Pennsylvania, Philadelphia, provides a molecular mechanism by which a protein known as PAX5 promotes the growth of a number of types of lymphoma.

Two years or more of oral steroid treatment decreases the risk of rheumatoid arthritis (RA) related lymphoma, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology, in Barcelona, Spain. Furthermore, these effects were found regardless of when in the course of the disease the steroids were first administered. However, these beneficial effects were not observed if the steroids were taken for less than a two year period.

Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had not had a relapse of their disease, according to researchers from the University of Michigan Comprehensive Cancer Center.